The independent source for health policy research, polling, and news.
December 12, 2016
Originally published in The Los Angeles Times, this perspective examines the potential implications for the individual market if key parts of the Affordable Care Act were repealed without a replacement plan.
Column Read PostDecember 9, 2016
In this Wall Street Journal Think Tank column, Drew Altman discusses new data highlighting why pre-exisitng conditions could be a flashpoint issue in the Affordable Care Act repeal and replace debate.
Column Read PostDecember 2, 2016
In this Wall Street Journal Think Tank column Drew Altman discusses how Republicans will assume ownership of health care’s policy and political problems as they assume control, and how that may affect their plans for the Affordable Care Act, Medicaid and Medicare.
Column Read PostNovember 21, 2016
This column was published as a Wall Street Journal Think Tank column on November 21, 2016. Early media coverage of the Republican health-care agenda has concentrated on plans to repeal and then replace the Affordable Care Act. The larger story is GOP preparations for a health policy trifecta: to fundamentally change the…
Column Read PostNovember 3, 2016
This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.
Read PostOctober 26, 2016
In this Wall Street Journal Think Tank column, Drew Altman discusses why the real moment of truth in assessing the stability of the Affordable Care Act’s health care Marketplaces may come next spring.
Column Read Post